Paper: Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results from a Phase Ib/II Study
Here is another combination of a CD3-CD20 BITE and polatuzumab in R/R aggressive B cell lymphoma. This phase I/II enrolled 63 patients to date with 24 having received prior CART. The ORR was 65%, CR 48% with similar rate seen in patients with prior CART. 21% had grade 3/4 neutropenia.
